SWOT analysis of Bangladesh Pharmaceuticals And Healthcare Industry
While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company – it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Bangladeshi healthcare sector, we have identified those emanating from the state’s political/economic profile (such as high inflation) and industry specific dangers (such as low per-capita spending and poor access to healthcare facilities) that call into question the likelihood of anticipated returns being realised over the assessed time period. Headline Expenditure Projections Pharmaceuticals: BDT111.10bn (US$1.50bn) in 2011 to BDT124.15bn (US$1.52bn) in 2012; +11.7% in local currency terms and +1.1% in US dollar terms. Healthcare: BDT271.27bn (US$3.66bn) in 2011 to BDT304.45bn (US$3.72bn) in 2012; +12.2% in local currency terms and +1.6% in US...